Performance Disclosure - Muyuan Foods reported a revenue of 76.463 billion yuan for the first half of 2025, representing a year-on-year increase of 34.46%, with a net profit attributable to shareholders of 10.53 billion yuan, up 1169.77% year-on-year [1] - Shanghai Petrochemical reported a revenue of 39.52 billion yuan for the first half of 2025, a year-on-year decrease of 9.2%, with a net loss attributable to shareholders of 462 million yuan, transitioning from profit to loss [2] - Fuhuan Microelectronics reported a revenue of 688 million yuan for the first half of 2025, a year-on-year decrease of 14.04%, with a net profit attributable to shareholders of approximately 23.02 million yuan, down 78.1% year-on-year [3] Shareholding Changes - Botao Bio announced that its actual controller, Yu Xiuping, plans to reduce holdings by no more than 3% of the company's total shares, equating to approximately 4.48 million shares [4] - Sanbo Brain Science announced that shareholder TBP 3Doctors (HK) Limited plans to reduce holdings by no more than approximately 609,000 shares, accounting for 3% of the total share capital after excluding shares in the repurchase account [5] - Xiangshan Co. announced that two shareholders, Zhao Yukun and Chen Bo, reduced their holdings by a total of 5.45% of the company's shares, equating to 7.1996 million shares, with the reduction plan completed [6] Risk Matters - ST Zhongdi announced that 23.77% of the shares held by its controlling shareholder, totaling 71.1448 million shares, will be publicly auctioned from September 24 to 25, 2025, due to debt disputes, which may lead to a change in company control if the auction is successful [7] - Kailong Co. announced that its subsidiaries were fined a total of 1.762 million yuan for reaching a fixed price monopoly agreement, which is expected to reduce the company's net profit by approximately 1.3962 million yuan [8] - Tiansheng New Materials reported that Baoding Weishai New Materials Technology Co., Ltd. filed an appeal involving an amount of 802 million yuan, seeking to overturn a previous court ruling [9]

Performance Disclosure - Muyuan Foods reported a revenue of 76.463 billion yuan for the first half of 2025, representing a year-on-year increase of 34.46%, with a net profit attributable to shareholders of 10.53 billion yuan, up 1169.77% year-on-year [1] - Shanghai Petrochemical reported a revenue of 39.52 billion yuan for the first half of 2025, a year-on-year decrease of 9.2%, with a net loss attributable to shareholders of 462 million yuan, transitioning from profit to loss [2] - Fuhuan Microelectronics reported a revenue of 688 million yuan for the first half of 2025, a year-on-year decrease of 14.04%, with a net profit attributable to shareholders of approximately 23.02 million yuan, down 78.1% year-on-year [3] Shareholding Changes - Botao Biological announced that its actual controller, Yu Xiuping, plans to reduce holdings by no more than 3% of the company's total shares, equating to approximately 4.48 million shares [4] - Sanbo Brain Science announced that shareholder TBP 3Doctors (HK) Limited plans to reduce holdings by no more than approximately 609,000 shares, representing 3% of the total share capital after excluding shares in the repurchase account [5] - Xiangshan Co. announced that two shareholders, Zhao Yukun and Chen Bo, reduced their holdings by a total of 5.45% of the company's shares, equating to 7.1996 million shares, with the reduction plan completed [6] Risk Matters - ST Zhongdi announced that 23.77% of the shares held by its controlling shareholder, totaling 71.1448 million shares, will be publicly auctioned from September 24 to 25, 2025, due to debt disputes, which may lead to a change in company control [7] - Kailong Co. announced that its subsidiaries were fined a total of 1.762 million yuan for reaching a fixed price monopoly agreement, which is expected to reduce the company's net profit by approximately 1.3962 million yuan [8] - Tiansheng New Materials reported that Baoding Weishai New Materials Technology Co., Ltd. filed an appeal involving an amount of 802 million yuan, seeking to overturn a previous court ruling [9]

Group 1 - The stock price of Sanbo Brain Science closed at 63.72 yuan on August 20, 2025, down by 2.44 yuan, a decrease of 3.69% from the previous trading day [1] - The trading volume on that day was 227,709 hands, with a transaction amount of 1.451 billion yuan [1] - Sanbo Brain Science is a medical service provider focused on neurosurgery, with main businesses including medical services and supply chain operations [1] Group 2 - The company announced that a shareholder holding more than 5% of shares, TBP3Doctors (HK) Limited, plans to reduce its holdings by up to 6.09 million shares, accounting for 3% of the total share capital, within the next three months [1] - The reduction will occur through a centralized bidding method for up to 2.03 million shares and through block trading for up to 4.06 million shares [1] - On August 20, the net outflow of main funds for Sanbo Brain Science was 269.69 million yuan, representing 2.63% of the circulating market value [1]

Core Viewpoint - TBP 3Doctors (HK) Limited plans to reduce its stake in Sanbo Brain Science (301293) by up to 6.0897 million shares, representing 3% of the total share capital after excluding shares in the company's repurchase account [1] Summary by Relevant Sections - Shareholding Information - TBP currently holds 31.2054 million shares in Sanbo Brain Science, which accounts for 15.37% of the total share capital after excluding shares in the company's repurchase account [1]

格隆汇8月20日丨三博脑科(301293.SZ)公布，持有公司股份31,205,425股(占剔除公司回购专用账户股份 数量后总股本的15.37%)的持股5%以上股东TBP 3Doctors(HK)Limited(简称"TBP")计划在公告披露之日 起十五个交易日后的三个月内以集中竞价和大宗交易方式减持公司股份不超过6,089,694股(占剔除公司 回购专用账户股份数量后总股本的3.00%)。其中，通过集中竟价方式减持不超过2,029,898股(占剔除公 司回购专用账户股份数量后总股本的1.00%)，通过大宗交易方式减持不超过4,059,796股(占剔除公司回 购专用账户股份数量后总股本的2.00%)。 ...

来源：新浪证券-红岸工作室 三博脑科医院管理集团股份有限公司（以下简称"三博脑科"）近日发布关于持股5%以上股东减持股份 的预披露公告，股东TBP 3Doctors (HK) Limited计划减持公司股份。 减持股东及股份情况 TBP 3Doctors (HK) Limited目前持股数量为31,205,425股，占剔除公司回购专用账户股份数量后总股本 的15.37%，其所持股份全部为无限售条件流通股。股份来源为公司首次公开发行股票并上市前持有的 股份以及该等股份上市后资本公积金转增股本取得的股份。 减持计划详情 减持数量及占比：计划减持6,089,694股，占剔除公司回购专用账户股份数量后总股本的3.00%。其中， 通过集中竞价方式减持不超过2,029,898股（占剔除公司回购专用账户股份数量后总股本的1.00%），通 过大宗交易方式减持不超过4,059,796股（占剔除公司回购专用账户股份数量后总股本的2.00%）。若计 划减持期间内有派息、送股等除权除息事项，减持股份数将相应进行调整。 减持期间：自本公告披露之日起15个交易日后的3个月内。 减持价格：根据减持时的市场价格确定，并根据集中竞价、大宗交易 ...

三博脑科公告，持股5%以上股东TBP 3Doctors (HK) Limited计划在本公告披露之日起十五个交易日后的 三个月内以集中竞价和大宗交易方式减持本公司股份不超过6089694股（占剔除公司回购专用账户股份 数量后总股本的3.00%）。其中，通过集中竟价方式减持不超过2029898股（占剔除公司回购专用账户 股份数量后总股本的1.00%），通过大宗交易方式减持不超过4059796股（占剔除公司回购专用账户股 份数量后总股本的2.00%）。 (本文来自第一财经) ...

三博脑科（SZ 301293，收盘价：63.72元）8月20日晚间发布公告称，持有三博脑科医院管理集团股份 有限公司股份约3121万股（占剔除公司回购专用账户股份数量后总股本的15.37%）的持股5%以上股东 TBP 3Doctors (HK) Limited（简称"TBP"）计划在本公告披露之日起十五个交易日后的三个月内以集中 竞价和大宗交易方式减持公司股份不超过约609万股（占剔除公司回购专用账户股份数量后总股本的 3%）。其中，通过集中竟价方式减持不超过约203万股（占剔除公司回购专用账户股份数量后总股本的 1%），通过大宗交易方式减持不超过约406万股（占剔除公司回购专用账户股份数量后总股本的 2%）。 2024年1至12月份，三博脑科的营业收入构成为：医疗占比99.67%，供应链占比0.33%。 （文章来源：每日经济新闻） ...

证券代码：301293 证券简称：三博脑科 公告编号：2025-028 三博脑科医院管理集团股份有限公司 关于持股 5%以上股东减持股份的预披露公告 公司股东 TBP 3Doctors (HK) Limited 保证向本公司提供的信息内容真实、准 确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 持有三博脑科医院管理集团股份有限公司（以下简称"公司"）股份 31,205,425 股（占剔除公司回购专用账户股份数量后总股本的 15.37%）的持股 5%以上股东 TBP 3Doctors (HK) Limited（以下简称"TBP"）计划在本公告披露之日起十五个 交易日后的三个月内以集中竞价和大宗交易方式减持本公司股份不超过 6,089,694 股（占剔除公司回购专用账户股份数量后总股本的 3.00%）。其中，通 过集中竟价方式减持不超过 2,029,898 股（占剔除公司回购专用账户股份数量后 总股本的 1.00%），通过大宗交易方式减持不超过 4,059,796 股（占剔除公司回 购专用账户股份数量后总股本的 2.00%）。 一、股 ...

Group 1 - The core viewpoint of the article highlights that Sanbo Brain Science's stock closed at 63.72 yuan, down 3.69%, with a rolling PE ratio of 119.43 times and a total market capitalization of 13.125 billion yuan [1] - In comparison to the industry, the average PE ratio for the medical services sector is 49.21 times, with a median of 65.65 times, placing Sanbo Brain Science at the 39th position in the industry ranking [1] - As of March 31, 2025, the number of shareholders for Sanbo Brain Science increased to 37,673, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - Sanbo Brain Science Hospital Management Group Co., Ltd. primarily engages in clinical medical services, with its main products including medical services, pharmaceuticals, supply chain, and other businesses [1] - The latest quarterly report for Q1 2025 shows that the company achieved an operating income of 393 million yuan, representing a year-on-year increase of 16.78%, and a net profit of 38.3136 million yuan, up 14.56%, with a gross profit margin of 26.44% [1]